115 related articles for article (PubMed ID: 11753653)
21. Analyses of the tumour suppressor ING1 expression and gene mutation in human basal cell carcinoma.
Chen B; Campos EI; Crawford R; Martinka M; Li G
Int J Oncol; 2003 Apr; 22(4):927-31. PubMed ID: 12632089
[TBL] [Abstract][Full Text] [Related]
22. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
23. An intronic variant in the TP53 gene in a Brazilian woman with breast cancer.
Lacerda LL; Serrano SV; Mathes A; Rey JA; Bello MJ; Casartelli C
Cancer Genet Cytogenet; 2005 Jul; 160(2):160-3. PubMed ID: 15993272
[TBL] [Abstract][Full Text] [Related]
24. Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma.
Chou HC; Chen CH; Lee HS; Lee CZ; Huang GT; Yang PM; Lee PH; Sheu JC
Cancer Lett; 2007 Aug; 253(1):138-43. PubMed ID: 17324501
[TBL] [Abstract][Full Text] [Related]
25. Concomitant inactivation of p53 and Chk2 in breast cancer.
Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; Osin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T
Oncogene; 2002 Feb; 21(9):1316-24. PubMed ID: 11857075
[TBL] [Abstract][Full Text] [Related]
26. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
27. ei24, a p53 response gene involved in growth suppression and apoptosis.
Gu Z; Flemington C; Chittenden T; Zambetti GP
Mol Cell Biol; 2000 Jan; 20(1):233-41. PubMed ID: 10594026
[TBL] [Abstract][Full Text] [Related]
28. Alterations in the suppressor gene PPP2R1B in parathyroid hyperplasias and adenomas.
Hemmer S; Wasenius VM; Haglund C; Zhu Y; Knuutila S; Franssila K; Joensuu H
Cancer Genet Cytogenet; 2002 Apr; 134(1):13-7. PubMed ID: 11996789
[TBL] [Abstract][Full Text] [Related]
29. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer.
Nayak BK; Baral RN; Das BR
Neoplasma; 1996; 43(5):305-10. PubMed ID: 8996549
[TBL] [Abstract][Full Text] [Related]
30. A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region.
Baysal BE; Willett-Brozick JE; Taschner PE; Dauwerse JG; Devilee P; Devlin B
Eur J Hum Genet; 2001 Feb; 9(2):121-9. PubMed ID: 11313745
[TBL] [Abstract][Full Text] [Related]
31. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers.
Costa A; Marasca R; Valentinis B; Savarino M; Faranda A; Silvestrini R; Torelli G
J Pathol; 1995 May; 176(1):45-53. PubMed ID: 7616356
[TBL] [Abstract][Full Text] [Related]
32. Mutations of p53 gene in breast cancer in the Egyptian province of Dakahliya.
El-Ghannam DM; Arafa M; Badrawy T
J Oncol Pharm Pract; 2011 Jun; 17(2):119-24. PubMed ID: 20015931
[TBL] [Abstract][Full Text] [Related]
33. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
34. Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3.
Cleton-Jansen AM; Moerland EW; Pronk JC; van Berkel CG; Apostolou S; Crawford J; Savoia A; Auerbach AD; Mathew CG; Callen DF; Cornelisse CJ
Br J Cancer; 1999 Mar; 79(7-8):1049-52. PubMed ID: 10098735
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: clinical and prognostic implications.
Mazumder Indra D; Mitra S; Singh RK; Dutta S; Roy A; Mondal RK; Basu PS; Roychoudhury S; Panda CK
Int J Cancer; 2011 Oct; 129(8):1859-71. PubMed ID: 21154811
[TBL] [Abstract][Full Text] [Related]
36. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer.
Pulido HA; Fakruddin MJ; Chatterjee A; Esplin ED; Beleño N; Martinez G; Posso H; Evans GA; Murty VV
Cancer Res; 2000 Dec; 60(23):6677-82. PubMed ID: 11118052
[TBL] [Abstract][Full Text] [Related]
37. Allele-specific loss of heterozygosity at the DAL-1/4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation.
Kittiniyom K; Mastronardi M; Roemer M; Wells WA; Greenberg ER; Titus-Ernstoff L; Newsham IF
Genes Chromosomes Cancer; 2004 Jul; 40(3):190-203. PubMed ID: 15138999
[TBL] [Abstract][Full Text] [Related]
38. Absence of PPP2R1B gene alterations in primary ovarian cancers.
Campbell IG; Manolitsas T
Oncogene; 1999 Nov; 18(46):6367-9. PubMed ID: 10597236
[TBL] [Abstract][Full Text] [Related]
39. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.
Prosser J; Thompson AM; Cranston G; Evans HJ
Oncogene; 1990 Oct; 5(10):1573-9. PubMed ID: 2250913
[TBL] [Abstract][Full Text] [Related]
40. Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation.
Popović Hadzija M; Radosevic S; Kovacević D; Lukac J; Hadzija M; Spaventi R; Pavelić K; Kapitanović S
Mutat Res; 2004 Apr; 548(1-2):61-73. PubMed ID: 15063137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
